NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions

@@ Property / budget @@
+,136,308.0 EuroAmount 1,136,308.0 Euro
Unit Euro
-Amount
+,136,308.0 Euro
-Unit
+Euro
@@ Property / budget: 1,136,308.0 Euro / rank @@
+Normal rank
@@ Property / EU contribution @@
+,221.0 EuroAmount 891,221.0 Euro
Unit Euro
-Amount
+,221.0 Euro
-Unit
+Euro
@@ Property / EU contribution: 891,221.0 Euro / rank @@
+Normal rank
@@ Property / co-financing rate @@
+.43 percentAmount 78.43 percent
Unit percent
-Amount
+.43 percent
-Unit
+percent
@@ Property / co-financing rate: 78.43 percent / rank @@
+Normal rank

Revision as of 06:40, 22 October 2021

Project Q2907213 in Portugal

Language	Label	Description	Also known as
English	NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis	Project Q2907213 in Portugal